A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

Starting soon

Conditions studied: Complement 3 Glomerulopathy

In brief

This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.

Key facts

Study ID

NCT07598448

Run by

Novartis Pharmaceuticals

People needed

35

Starts

2026-08-23

Expected to finish

2026-12-15

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (≥18 years).
• Biopsy-confirmed C3G.
• Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.

You may not qualify if…

• Patients treated with iptacopan through an EAP for indications other than C3G.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.